Short term treatment enhanced tumour infiltration of CD8+ T-cells, which subsequently decreased, but combining short term BRAF and MEK inhibitor therapy with anti-PD-1 ICB increased their anti-tumour activity [181]. The gene discussed is CD8A; the disease is neoplasm.